<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00926627</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT - 2007-005117-18</org_study_id>
    <nct_id>NCT00926627</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Bosentan in Progressive Pulmonary Sarcoidosis</brief_title>
  <acronym>BOPSAC</acronym>
  <official_title>A Prospective Randomized, Double Blind, Placebo-controlled, Safety and Efficacy Study of Bosentan as add-on Therapy in Progressive Pulmonary Sarcoidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daniel Doberer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Progressive pulmonary sarcoidosis occurs in up to twenty percent of patients who require&#xD;
      persistent treatment, but available treatment options have shown considerable long-term&#xD;
      toxicity and uncertain or unproven efficacy. In these patients, pulmonary fibrosis and&#xD;
      pulmonary hypertension are common complications which have major prognostic impact.&#xD;
      Endothelin-1 (ET-1) has been demonstrated to play a key role in pulmonary fibrosis and&#xD;
      pulmonary hypertension, and a potential role in pulmonary sarcoidosis. ET-1 is a potent&#xD;
      vasoconstrictor and can promote fibrosis, cell proliferation, and remodeling, and is&#xD;
      pro-inflammatory. Preliminary data have shown the therapeutic potential of the endothelin&#xD;
      receptor antagonist (ERA) bosentan in sarcoidosis associated pulmonary hypertension.&#xD;
&#xD;
      In this light, the therapeutic potential of bosentan as an add-on treatment in progressive&#xD;
      pulmonary sarcoidosis needs to be evaluated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Not enough patients with the specified criteria could not&#xD;
  </why_stopped>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment efficacy is assessed by a composite clinical score, including six parameters: Pulmonary function test (FVC and DLCO), Blood gas analysis (AaDO2), HRCT (Oberstein score), 6 minute walk test (6-MWD), Dyspnoea (ATS dyspnea scale)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess safety and tolerability of bosentan in progressive pulmonary sarcoidosis</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the efficacy of bosentan treatment in the subgroups of patents with and without sarcoidosis-associated pulmonary hypertension.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Sarcoidosis</condition>
  <condition>Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo b.i.d.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bosentan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>62.5 mg/125 mg bosentan b.i.d.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bosentan</intervention_name>
    <description>62.5 mg tablets b.i.d. administered orally for 4 weeks followed by the maintenance dose of 125 mg b.i.d. (62.5 mg b.i.d. if body weight &lt; 40 kg/90 lb)</description>
    <arm_group_label>Bosentan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>identical preparation as the study drug, but without the active substance, administered b.i.d.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent prior to any study-mandated procedure.&#xD;
&#xD;
          -  Male and female patients aged &gt; 18 and &lt; 70 years.&#xD;
&#xD;
          -  Histologically proven sarcoidosis diagnosed at least one year before screening.&#xD;
&#xD;
          -  Diagnosis of sarcoidosis and with evidence of pulmonary parenchymal disease on chest&#xD;
             X-ray or CT (radiological stage II, III) with or without pulmonary hypertension.&#xD;
             Subjects with concurrent extrapulmonary sarcoidosis are encouraged to be enrolled.&#xD;
&#xD;
          -  Progressive disease, defined as follows:&#xD;
&#xD;
               -  Deterioration in the 3-12 month period prior to screening in at least two of the&#xD;
                  following criteria:&#xD;
&#xD;
                    -  increase in clinical symptoms (cough, shortness of breath, chest pain,&#xD;
                       fatigue or hemoptysis).&#xD;
&#xD;
                    -  lung function: decrease of 10% in TLC, FVC or DLCO.&#xD;
&#xD;
                    -  worsening of radiographic opacities.&#xD;
&#xD;
               -  Have been receiving pre-study treatment with prednisolone (or equivalent dose of&#xD;
                  corticosteroid) as a single agent (â‰¥ 10 mg/day) or other immunosuppressants&#xD;
                  (methotrexate, azathioprine, cyclophosphamide, TNF inhibitors, etc.) within the&#xD;
                  3-month period immediately prior to screening. Patients must be on a stable dose&#xD;
                  of these medications for &gt; 4 weeks before starting the study medication.&#xD;
&#xD;
          -  AST and ALT values within three times upper limit of normal.&#xD;
&#xD;
          -  Ability to communicate well with the investigator, in the local language, and to&#xD;
             understand and comply with the requirements of the study.&#xD;
&#xD;
          -  Negative pregnancy test in female patients.&#xD;
&#xD;
          -  Adequate contraception in female patients of childbearing age.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity to any excipients of the drug formulation or to bosentan.&#xD;
&#xD;
          -  Treatment with another investigational drug within 3 months prior to screening.&#xD;
&#xD;
          -  Pulmonary sarcoidosis:&#xD;
&#xD;
               -  without disease progression as defined above&#xD;
&#xD;
               -  with radiological stage I&#xD;
&#xD;
               -  with radiological stage IV (pulmonary fibrosis with evidence of honey-combing,&#xD;
                  hilar retraction, bullae and cysts)&#xD;
&#xD;
          -  Other cause of pulmonary disease:&#xD;
&#xD;
               -  Active tuberculosis (or positive Quantiferon test), fungi infection, lymphoma.&#xD;
&#xD;
               -  Chronic obstructive pulmonary disease, asthma, interstitial lung disease other&#xD;
                  than sarcoid-related&#xD;
&#xD;
          -  Anamnesis of beryllium or asbestos exposition&#xD;
&#xD;
          -  Previous smoking (&gt; 10 PY), or active smoker&#xD;
&#xD;
          -  Previous administration of bosentan&#xD;
&#xD;
          -  Positive results from the hepatitis serology, except for vaccinated subjects, at&#xD;
             screening.&#xD;
&#xD;
          -  Positive results from the HIV serology at screening.&#xD;
&#xD;
          -  Malignancy requiring chemotherapy or radiation&#xD;
&#xD;
          -  Uncontrolled other disease like&#xD;
&#xD;
               -  Chronic heart failure (NYHA III, IV)&#xD;
&#xD;
               -  Diabetes mellitus (blood glucose 2x per day &gt; 250 mg/dl , HbA1c &gt; 10 %)&#xD;
&#xD;
               -  Arterial hypertension (SBP &gt; 180 mmHg)&#xD;
&#xD;
          -  Concomitant treatment with cyclosporine A&#xD;
&#xD;
          -  Concomitant treatment with tacrolimus or sirolimus&#xD;
&#xD;
          -  Concomitant treatment with glibenclamide&#xD;
&#xD;
          -  Are pregnant, nursing, or planning pregnancy during the trial or within six month&#xD;
             period thereafter.&#xD;
&#xD;
          -  Have a known substance dependency (drug or alcohol within 3 years of screening).&#xD;
&#xD;
          -  Presumed non-compliance.&#xD;
&#xD;
          -  Legal incapacity or limited legal capacity at screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Doberer, MD, MSc</last_name>
    <role>Study Director</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>General Hospital Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilhelminenspital Wien</name>
      <address>
        <city>Vienna</city>
        <zip>1180</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <link>
    <url>http://www.meduniwien.ac.at/klpharm/</url>
    <description>Department of Clinical Pharmacology of the Medical University of Vienna</description>
  </link>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>June 22, 2009</study_first_submitted>
  <study_first_submitted_qc>June 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2009</study_first_posted>
  <last_update_submitted>September 14, 2016</last_update_submitted>
  <last_update_submitted_qc>September 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Daniel Doberer</investigator_full_name>
    <investigator_title>Research Associate</investigator_title>
  </responsible_party>
  <keyword>endothelin receptor antagonist</keyword>
  <keyword>bosentan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Sarcoidosis, Pulmonary</mesh_term>
    <mesh_term>Sarcoidosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bosentan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

